Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05424640
Other study ID # RTKU
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2022
Est. completion date July 31, 2022

Study information

Verified date February 2023
Source Center of Food and Fermentation Technologies
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this dietary intervention is to study the effects of several dietary fibers on the gut microbiota at the personal level. Hypothesis 1: Intake of specific dietary fibers improves the blood lipid profile depending on the personal microbiota of the participants. Hypothesis 2: detailed food intake analysis and continuous monitoring of gut microbiota enables to draw causative interrelationships between food components, bacteria of gut microbiome and health characteristics.


Description:

The study design is a cross-over, pre-post intervention trial. All participants are enrolled into all study periods. Study consists of baseline period, four periods of dietary fiber intervention and four periods of wash-outs. The main goal of this study was to elucidate the patterns between individual dietary fibers and gut microbiota at the personal level. Each person has a unique (individual) intestinal microbiological profile that changes according to lifestyle (diet, environment, physical activity), age and health status. With next generation sequencing methods to map microbial communities and detailed nutritional analysis including blood tests, it is possible to identify the specific effects of specific fiber on a selected (individual) microbiota. TFTAK researchers have long-term experience in microbiota analysis as well as diet design and nutrition analysis, which can be successfully applied in this project. PRELIMINARY STUDY EVALUATION AND TESTING 1. Complete preliminary study questionnaire 2. Complete orientation to the study and provide voluntary consent to join the study 3. Collection of coded intervention products, sampling supplies, and instructional materials 1-WEEK QUESTIONNAIRE AND LABORATORY VISIT 1. Record food intake and gastrointestinal function for 7 days 2. Collect health data and provide a 7-day food diary using web-based program Nutridata (tap.nutridata.ee) 3. Provide a stool and blood sample at the laboratory 3-WEEK QUESTIONNAIRE AND LABORATORY VISITS 1. Record food intake and gastrointestinal symptoms for 7 days 2. Collect health data and provide a 3-day food frequency questionnaire 3. Provide a stool and blood sample at the laboratory BLOOD SAMPLE ANALYSES 1. Provide the blood sample at the laboratory in the morning in an overnight fasted state. DIETARY INTERVENTION Study consists of baseline period, four periods of dietary fiber intervention and four periods of wash-outs: 1. Baseline mapping (health questionnaire, 1 week food diary before sampling of blood and gut microbiota) 2. Dietary fiber 1, 3 weeks, analyses: health questionnaire, 1 week food diary before sampling of blood and gut microbiota 3. Wash-out period, 2 weeks, analyses: health questionnaire, 1 week food diary before sampling of blood and gut microbiota 4. Repeating 3 times periods of 2 and 3. In each dietary fiber period 15 g/day of oat fiber, rye fiber, mix I and mix II of dietary fibers are used as test compounds. Dietary fiber mix I and mix II are inulin, beta-glucan, polydextrose, citrus pectin and psyllium, and beta-glucan, citrus pectin and psyllium, respectively.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date July 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria: - Age 20-60 - Normal bowel function - Omnivorous diet - Ability to provide a signed written informed consent - Willing to provide stool and blood specimens over the 22-week study period Exclusion Criteria: - Diagnosed history of chronic diseases including coronary heart disease, stroke, cancer, type 1 or 2 diabetes mellitus, inflammatory bowel disease, gastritis, autoimmune disease, or rheumatoid arthritis - Medication: statins, blood pressure medications, antidepressants, other prescription medications - History of bariatric operation, removal of the gallbladder. - Food allergies, lactose intolerance - Recent (previous 3 months) use of antibiotics - Intake of highly dosed pre- or probiotics 2 weeks prior and during the study - Current pregnancy or breastfeeding - Volunteers showing previously unrecognized illness will also be excluded - Individual unable to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Dietary fiber 1
Description in the arm description
Dietary fiber 2
Description in the arm description
Dietary fiber 3
Description in the arm description
Dietary fiber 4
Description in the arm description

Locations

Country Name City State
Estonia Center of Food and Fermentation Technologies Tallinn Harjumaa

Sponsors (1)

Lead Sponsor Collaborator
Center of Food and Fermentation Technologies

Country where clinical trial is conducted

Estonia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the intestinal microbiota Fecal microbiota analysis based on the 16S ribosomal RNA (rRNA) sequencing pre- and post-dietary intervention. 150 days
Primary Evaluation of food consumption data All foods consumed were collected 1 week before the end of every study period using web-based program (tap.nutridata.ee) 150 days
Primary Evaluation of blood lipid profile Triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol after every intervention and wash-out in plasma (mmol/L). 150 days
Primary Evaluation of blood glucose levels Fasting glucose pre- and post-dietary intervention in plasma (mmol/L). 150
Primary Evaluation of liver characteristics profile Uric acid, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyltransferase (GGT) after every intervention and wash-out in plasma (mmol/L). 150
Secondary Evaluation of the stool form Stool form will be assessed using a validated 7-point scale called Bristol Stool Form Scale pre- and post-dietary intervention. 150 days
Secondary Evaluation of the defecation frequency Evacuation frequency 7 days before every blood and microbiome sampling.
Evacuation frequency (number of bowel movements per week) pre- and post-dietary intervention.
150
Secondary Evaluation of the gastrointestinal symptoms Frequency and severity of the gastrointestinal symptoms (Constipation, Diarrhea, Bloating, Flatulence, Cramps, Stomach pain). Scale of frequency: Never, Less than 10 times a year, Once a month, Once a week, Every day. Scale of severity: I do not have any gastrointestinal symptoms, Mild (does not disturb), Moderate, Strong (disturbs considerably). 150
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1